PD-1 antibodies
US10913801B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2017 |
| Grant date | Feb 9, 2021 |
| Priority date | — |
| Expiry date | Sep 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.